Related Experiment Video
Updated: Jul 25, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
[Targeting microRNA-125b inhibited the metastasis of Alisertib resistance cells through mediating p53 pathway]
1Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Jiangsu Province Key Laboratory of Immunity and Metabolism, National Experimental Teaching Demonstration Center of Basic Medicine, Xuzhou Medical University, Xuzhou 221000, China.
Abstract:
Objective: To clarify the mechanisms involvement in Alisertib-resistant colorectal cells and explore a potential target to overcome Alisertib-resistance. Methods: Drug-resistant colon cancer cell line (named as HCT-8-7T cells) was established and transplanted into immunodeficient mice. The metastasis in vivo were observed. Proliferation and migration of HCT-8-7T cells and their parental cells were assessed by colony formation and Transwell assay, respectively. Glycolytic capacity and glutamine metabolism of cells were analyzed by metabolism assays. The protein and mRNA levels of critical factors which are involved in mediating glycolysis and epithelial-mesenchymal transition (EMT) were examined by western blot and reverse transcription-quantitative real-time polymerase chain reaction(RT-qPCR), respectively. Results: In comparison with the mice transplanted with HCT-8 cells, which were survival with limited metastatic tumor cells in organs, aggressive metastases were observed in liver, lung, kidney and ovary of HCT-8-7T transplanted mice (P<0.05). The levels of ATP [(0.10±0.01) mmol/L], glycolysis [(81.77±8.21) mpH/min] and the capacity of glycolysis [(55.50±3.48) mpH/min] in HCT-8-7T cells were higher than those of HCT-8 cells [(0.04±0.01) mmol/L, (27.77±2.55) mpH/min and(14.00±1.19) mpH/min, respectively, P<0.05]. Meanwhile, the levels of p53 protein and mRNA in HCT-8-7T cells were potently decreased as compared to that in HCT-8 cells (P<0.05). However, the level of miRNA-125b (2.21±0.12) in HCT-8-7T cells was significantly elevated as compared to that in HCT-8 cells (1.00±0.00, P<0.001). In HCT-8-7T cells, forced-expression of p53 reduced the colon number (162.00±24.00) and the migration [(18.53±5.67)%] as compared with those in cells transfected with control vector [274.70±40.50 and (100.00±29.06)%, P<0.05, respectively]. Similarly, miR-125b mimic decreased the glycolysis [(25.28±9.51) mpH/min] in HCT-8-7T cells as compared with that [(54.38±12.70)mpH/min, P=0.003] in HCT-8-7T cells transfected with control. Meanwhile, in comparison with control transfected HCT-8-7T cells, miR-125b mimic also significantly led to an increase in the levels of p53 and β-catenin, in parallel with a decrease in the levels of PFK1 and HK1 in HCT-8-7T cells (P<0.05). Conclusions: Silencing of p53 by miR-125b could be one of the mechanisms that contributes to Alisertib resistance. Targeting miR-125b could be a strategy to overcome Alisertib resistance.
Insights
MicroRNA-125b (miR-125b) may cause Alisertib resistance in colorectal cancer by silencing p53. Targeting miR-125b could be a strategy to overcome this resistance and reduce aggressive metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Context:
- Alisertib is a drug used in cancer treatment.
- Colorectal cancer cells can develop resistance to Alisertib.
- Understanding the mechanisms of resistance is crucial for developing effective therapies.
Purpose:
- To investigate the mechanisms underlying Alisertib resistance in colorectal cancer cells.
- To identify potential therapeutic targets to overcome Alisertib resistance.
Summary:
- Alisertib-resistant colorectal cancer cells (HCT-8-7T) exhibited increased glycolysis and metastasis compared to parental cells.
- These resistant cells showed decreased p53 levels and increased miR-125b levels.
- Restoring p53 or inhibiting miR-125b function reversed resistance phenotypes, reduced glycolysis, and altered key protein expressions.
Impact:
- This study reveals that miR-125b-mediated silencing of p53 contributes to Alisertib resistance in colorectal cancer.
- Targeting miR-125b presents a potential therapeutic strategy to overcome Alisertib resistance and inhibit cancer metastasis.
Related Concept Videos
MicroRNAs
Abnormal Proliferation
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules

